NCT01691924View on ClinicalTrials.gov

Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Parkinson Disease

Interventions

DRUG

PBF-509

DRUG

Placebo

Trial Locations (2)

08302

Palobiofarma S.L. (molecule owner), Mataró

08025

Cim- Sant Pau, HSCSP, Barcelona

Sponsors

Collaborators (1)

Palo Biofarma, S.L

All Listed Sponsors

collaborator

Palo Biofarma, S.L

INDUSTRY

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER